Dietary supplements and natural products in breast cancer trials

Frontiers in Bioscience - Elite

Volumn 4 E, Issue 1, 2012, Pages 546-567

  Kado, Karl ^a   Forsyth, Andrew ^a   Patel, Priyesh Ramesh ^a   Schwartz, Janice Ann ^a,b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antioxidants; Breast cancer; CAMs; Chemoprevention; Clinical trials; Complementary conventional therapy combinations; Coriolus vesicolor; Dietary supplements; Endocrine therapy; Grapeseed extract; Green tea polyphenols; Iscador P; Mistletoe extract; Natural health productchemotherapy combinations; Natural health products; Phytochemicals; Scutellaria barbata; Vitamin D; Vitamins and minerals

Indexed keywords

ALPHA TOCOPHEROL; CALCITRIOL; CAPECITABINE; COLECALCIFEROL; CYANOCOBALAMIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLIC ACID; GEMCITABINE; GERMANIUM; GLUTAMINE; ISOFLAVONE DERIVATIVE; IXABEPILONE; LACTIC ACID; OMEGA 3 ACID ETHYL ESTER; OMEGA 3 FATTY ACID; PACLITAXEL; PENTOXIFYLLINE; PRALATREXATE; PYRIDOXINE; RALOXIFENE; SOYBEAN PROTEIN; UBIDECARENONE; UBIQUINONE; UNINDEXED DRUG; UREA; VINCRISTINE; VISCUM ALBUM EXTRACT; VITAMIN D; BIOLOGICAL PRODUCT;

ADVANCED CANCER; ALTERNATIVE MEDICINE; ARTHROPATHY; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER PAIN; CANCER PREVENTION; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURGERY; CANCER SURVIVAL; COLORECTAL CANCER; DEPRESSION; DIET SUPPLEMENTATION; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; HAND FOOT SYNDROME; HUMAN; INTERVENTION STUDY; LOW DRUG DOSE; LYMPHEDEMA; MAMMOGRAPHY; MASTALGIA; MAXIMUM TOLERATED DOSE; MULTIMODALITY CANCER THERAPY; MUSCULOSKELETAL PAIN; MUSCULOSKELETAL STIFFNESS; NEOPLASM; NEUROPATHY; NONHUMAN; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL NEUROPATHY; PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RISK ASSESSMENT; RISK REDUCTION; SOLID TUMOR; SYSTEMATIC REVIEW; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT; BREAST TUMOR; CLINICAL TRIAL (TOPIC); DIET THERAPY;

ANIMALIA; CORIOLUS; SCUTELLARIA BARBATA;

BIOLOGICAL AGENTS; BREAST NEOPLASMS; CLINICAL TRIALS AS TOPIC; COMPLEMENTARY THERAPIES; DIETARY SUPPLEMENTS; HUMANS;

EID: 84860128688     PISSN: 19450494     EISSN: 19450508     Source Type: Journal    
DOI: 10.2741/399     Document Type: Article

References (78)

1. Smith B. D., G.L. Smith, A. Hurria, G.N. Hortobagyi, and T.A. Buchholz: Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol 27 (17):2758-65 (2009
2. Jemal A., R. Siegel, J. Xu, & E. Ward: Cancer Statistics, 2010. CA Cancer J Clin 60 (5):277 (2010)
3. Maughan K.L., M.S. Lutterbie, & P.S. Ham: Treatment of breast cancer. Am Fam Physician 81 (11), 1339-1346 (2010)
4. Alvarez R.H., V. Valero, G.N. Hortobagyi: Emerging targeted therapies for breast cancer. J Clin Oncol 28 (20):3366-79 (2010)
5. Jones, S.E.: Metastatic Breast Cancer: The Treatment Challenge. Clinical Breast Cancer 8 (3), 224-233 (2008)
6. Pal S.K., B.H. Childs, & M. Pegram: Emergence of nonanthracycline regimens in the adjuvant treatment of breast cancer. Breast Cancer Res Treat 119 (1), 25-32 (2010)
7. Giglio P. & M.R. Gilbert: Neurologic complications of cancer and its treatment. Curr Oncol Rep 12 (1), 50-9 (2010)
8. Sioka C. & A.P. Kyritsis: Central and peripheral nervous system toxicity of common chemotherapeutic agents. Cancer Chemother Pharmacol 63:761-767 (2009
9. Geffen, R.: Integrative Oncology for the Whole Person: A Multidimensional Approach to Cancer Care. Integr Cancer Ther 9, 105-121 (2010)
10. Prasad K.N.: Multiple dietary antioxidants enhance the efficacy of standard and experimental cancer therapies and decrease their toxicity. Integr Cancer Ther 3 (4), 310-22 (2004
11. Velicer C.M., & C.M. Ulrich: Vitamin and mineral supplement use among US adults after cancer diagnosis: A systematic review. J Clin Oncol 26 (4), 665-73 (2008)
12. Lawenda B.D., K.M. Kelly, E.J. Ladas, S.M. Sagar, A. Vickers, & J.B. Blumberg: Should supplemental antioxidant administration be avoided during chemotherapy and radiation therapy? J Natl Cancer Inst 100 (11), 773-83 (2008)
13. Wyatt G., A. Sikorskii, M.H. Rahbar, D. Victorson, & L. Adams: Intervention Fidelity: Aspects of Complementary and Alternative Medicine Research. Cancer Nurs 33 (5), 331-342 (2010))
14. Boon H.S., F. Olatunde, & S.M. Zick: Trends in complementary/ alternative medicine use by breast cancer survivors: comparing survey data from 1998 and 2005. BMC Womens Health 30 (7), 4 (2007)
15. Chen Z., K. Gu, Y. Zheng, W. Zheng, W. Lu, & X.O. Shu: The use of complementary and alternative medicine among Chinese women with breast cancer. J Altern Complement Med 14 (8), 1049-55 (2008)
16. Morris, K.T., N. Johnson, L. Homer, & D. Walts: A comparison of complementary therapy use between breast cancer patients and patients with other primary tumor sites. Am J Surg 179 (5), 407-411 (2000
17. Kremser T., A. Evans, A. Moore, K. Luxford, S. Begbie, A. Bensoussan, R. Marigliani, & H. Zorbas: Use of complementary therapies by Australian women with breast cancer. Breast 17 (4), 387-94 (2008))
18. Yildirim Y: Patterns of the use of complementary and alternative medicine in women with metastatic cancer. Cancer Nurs 33 (3), 194-200 (2010)
19. Pedersen C.G., S. Christensen, A.B. Jensen, & R. Zachariae: Prevalence, socio-demographic and clinical predictors of post-diagnostic utilisation of different types of complementary and alternative medicine (CAM) in a nationwide cohort of Danish women treated for primary breast cancer. Eur J Cancer 45 (18), 3172-81 (2009
20. Greenlee H., Hershman D.L., & Jacobson J.S.: Use of antioxidant supplements during breast cancer treatment: A comprehensive review. Breast Cancer Res Treat 115 (3), 437-52 (2009
21. Mueller C.M., P.L. Mai, J. Bucher, J.A. Peters, L.T. Loud, & M.H. Greene: Complementary and alternative medicine use among women at increased genetic risk of breast and ovarian cancer. BMC Complement Altern Med 30 (8), 17 (2008))
22. Carpenter C.L., P.A. Ganz, & L. Bernstein: Complementary and alternative therapies among very longterm breast cancer survivors. Breast Cancer Res Treat 116 (2), 387-96 (2009
23. Buettner C., C.H. Kroenke, R.S. Phillips, R.B. Davis, D.M. Eisenberg, & M.D.: Correlates of use of different types of complementary and alternative medicine by breast cancer survivors in the nurses' health study. Breast Cancer Res Treat 100 (2), 219-27 (2006)
24. Lee M.M., S.S. Lin, M.R. Wrensch, S.R. Adler, & D. Eisenberg: Alternative therapies used by women with breast cancer in four ethnic populations. J Natl Cancer Inst 92 (1),42-7 (2000
25. Hann, D., F. Baker, M. Denniston, & N. Entrekin: Long-term Breast Cancer Survivors' Use of Complementary Therapies: Perceived Impact on Recovery and Prevention of Recurrence. Integr Cancer Ther 4 (1), 14-20 (2005
26. Ganz P., K.A. Desmond, B. Leedham, J.H. Rowland, B.E. Meyerowitz, & T.R. Belin: Quality of life in longterm, disease-free survivors of breast cancer: A follow-up study. J Natl Cancer Inst 94, 39-49 (2002
27. Matthews A.K., A. Sellergren, D. Huo, M. List, & G. Fleming. Complementary and alternative medicine use among breast cancer survivors. J Altern Complement Med 13 (5), 555-62 (2007)
28. Takimoto, C.H.: Phase 0 clinical trials in oncology: A paradigm shift for early drug development? Cancer Chemother Pharmacol 63 (4), 703-9 (2009
29. Le Tourneau C., J.J. Lee, & L.L. Siu: Dose escalation methods in phase I cancer clinical trials. J Natl Cancer Inst 101 (10), 708-20 (2009
30. Giordano J., D. Boatwright, S. Stapleton, L. Huff: Blending the boundaries: steps toward an integration of complementary and alternative medicine into mainstream practice. J Altern Complement Med 8 (6):897-906 (2002
31. Gocek, E., & G. P. Studzinski: Vitamin D and differentiation in cancer. Crit Rev Clin Lab Sci 46 (4), 190-209 (2009
32. Kemmis, C.M., S.M. Salvador, K.M. Smith, & J. Welsh: Human mammary epithelial cells express CYP27B1 and are growth inhibited by 25-hydroxyvitamin D-3, the major circulating form of vitamin D-3. J Nutr 136 (4), 887-892 (2006
33. Welsh, J., J.A. Wietzke, G.M. Zinser, S. Smyczek, S. Romu, E. Tribble, J.C. Welsh, B. Byrne, & C.J. Narvaez: Impact of the Vitamin D3 receptor on growth-regulatory pathways in mammary gland and breast cancer. J Steroid Biochem Mol Biol 83, 85-92 (2002
34. Khan Q.J., P.S. Reddy, B.F. Kimler, P. Sharma, S.E. Baxa, A.P. O'Dea, J.R. Klemp, & C.J. Fabian: Effect of vitamin D supplementation on serum 25-hydroxy vitamin D levels, joint pain, and fatigue in women starting adjuvant letrozole treatment for breast cancer. Breast Cancer Res Treat 119 (1), 111-118 (2010)
35. John, E.M., G.G. Schwartz, D.M. Dreon, & J. Koo: Vitamin D and Breast Cancer Risk: The NHANES I Epidemiologic Follow-up Study, 1971-1975 to 1992. Cancer Epidemiol Biomarkers Prev 8 (5), 399-406 (1999)
36. Shin, M.H., M.D. Holmes, S.E. Hankinson, K. Wu, G.A. Colditz, & W.C. Willett: Intake of dairy products, calcium, and vitamin D and risk of breast cancer. J Natl Cancer Inst 94 (17), 1301-1310 (2002
37. Prentice R. L. & G.L. Anderson: The women?s health initiative: lessons learned. Annu Rev Public Health 29,131-150 (2008)
38. Goodwin, P.J., M. Ennis, K.I. Pritchard, J. Koo, & N. Hood: Prognostic effects of 25-dihydroxyvitamin D levels in early breast cancer. J Clin Oncol 27 (23), 3757-63 (2009
39. Hines SL, H.K. Jorn, K.M. Thompson, & J.M. Larson: Breast cancer survivors and vitamin D: A review. Nutrition 26 (3), 255-62 (2010)
40. Palmieri C., T. MacGregor, S. Girgis, & D. Vigushin: Serum 25-hydroxyvitamin-D levels in early and advanced breast cancer. J Clin Pathol 59, 1334-1336 (2006
41. Amir E., C.E. Simmons, O.C. Freedman, G. Dranitsaris, D.E. Cole, R. Vieth, W.S. Ooi, & M. Clemons: A phase 2 trial exploring the effects of high-dose (10,000 IU/day) vitamin D (3) in breast cancer patients with bone metastases. Cancer 116 (2), 284-91 (2010)
42. Crew K.D., E. Shane, S. Cremers, D.J. McMahon, D. Irani, & D.L. Hershman: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27, 2151-2156 (2009
43. Holick, M.F., & T.C. Chen: Vitamin D deficiency: A worldwide problem with health consequences. Am J Clin Nutr 87, 1080S-1086S (2008)
44. Crew K.D., E. Shane, S. Cremers, D.J. McMahon, D. Irani, & D.L. Hershman: High prevalence of vitamin D deficiency despite supplementation in premenopausal women with breast cancer undergoing adjuvant chemotherapy. J Clin Oncol 27, 2151-2156 (2009
45. Santini D., S. Galluzzo, B. Vincenzi, A. Boccoli, E. Ferraro, C. Lippi, V. Altomare, G. Tonini, & F. Bertoldo: Longitudinal evaluation of vitamin D plasma levels during anthracycline- and docetaxel-based adjuvant chemotherapy in early-stage breast cancer patients. Ann Oncol 21 (1),185- 186 (2010)
46. Zain J., & O. O'Connor: Pralatrexate: basic understanding and clinical development. Expert Opin Pharmacother 11 (10),1705-14 (2010)
47. Chiao T.B., A.J. Lee: Role of pentoxifylline and vitamin E in attenuation of radiation-induced fibrosis. Ann Pharmacother 39 (3), 516-22
48. Magnusson, M., P. Höglund, K. Johansson, C. Jönsson, F. Killander, P. Malmström, A. Weddig, & E. Kjellén: Pentoxifylline and vitamin E treatment for prevention of radiation-induced side-effects in women with breast cancer: A phase two, double-blind, placebo-controlled randomised clinical trial (Ptx-5) Eur J Cancer 45 (14), 2488-95 (2009
49. Bhagavan, van Dalen, H.N., & R.K. Chopra: Coenzyme Q10: absorption, tissue uptake, metabolism and pharmacokinetics. Free Radic Res 40 (5), 445-53 (2006
50. van Dalen, E.C., H.N. Caron, H.O. Dickinson, & L.C. Kremer: Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev 16 (2), CD003917 (2008)
51. Kienle G.S. & H. Kiene: Influence of Viscum album L (European Mistletoe) Extracts on Quality of Life in Cancer Patients: A Systematic Review of Controlled Clinical Studies. Integr Cancer Ther 9: 142-157 (2010)
52. Brooker S., S. Martin S, A. Pearson, D. Bagchi, J. Earl, L. Gothard, E. Hall, L. Porter, & J. Yarnold: Double-blind, placebo-controlled, randomised phase II trial of IH636 grape seed proanthocyanidin extract (GSPE) in patients with radiation-induced breast induration. Radiother Oncol 79 (1), 45-51 (2006
53. Fujiki H., M. Suganuma, K. Imai, & K. Nakachi: Green tea: cancer preventive beverage and/or drug. Cancer Lett 15, 188 (1-2):9-13 (2002)
54. Mukhtar H., & N. Ahmad: Tea polyphenols: prevention of cancer and optimizing health. Am J Clin Nutr 71 (6 Suppl), 1698S-702S (2000)
55. Nakachi, K., S. Matsuyama, S. Miyake, M. Suganuma, & K. Imai : Preventive effects of drinking green tea on cancer and cardiovascular disease: epidemiological evidence for multiple targeting prevention. BioFactors 13, 49-54 (2000)
56. Imai, K., K. Suga, & K. Nakachi: Cancer-preventive effects of drinking green tea among a Japanese population. Prev Med 26, 769-775 (1997)
57. Fujiki, H.: Two stages of cancer prevention with green tea. J Cancer Res Clin Oncol 125, 589-597 (1999)
58. Ogunleye, A.A., F. Xue, & K.B. Michels: Green tea consumption and breast cancer risk or recurrence: A metaanalysis. Breast Cancer Res Treat 119 (2), 477-84 (2010)
59. National Cancer Institute, Division of Cancer Prevention and Control, Chemoprevention Branch, and Agent Development Committee: Clinical development plan: tea extracts green tea polyphenols epigallocatechin gallate. J Cell Biochem 26S, 236-257 (1996
60. Cui J, & Y. Chisti: Polysaccharopeptides of Coriolus versicolor: physiological activity, uses, and production. Biotechnol Adv 21 (2), 109-22 (2003
61. Rugo H, E. Shtivelman, A. Perez, C. Vogel, S. Franco, E. Tan Chiu, M. Melisko, M. Tagliaferri, I. Cohen, M. Shoemaker, Z. Tran, D. Tripathy. Phase I trial and antitumor effects of BZL101 for patients with advanced breast cancer. Breast Cancer Res Treat. 105 (1):17-28 (2007)
62. Acetyl-L-carnitine. Monograph: Altern Med Rev 15 (1), 76-83 (2010)
63. Vanotti A, M. Osio, E. Mailland, C. Nascimbene, E. Capiluppi, & C. Mariani: Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. CNS Drugs 21 Suppl 1, 3-12 (2007)
64. De Grandis D.: Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: A short review. CNS Drugs 21 Suppl 1, 39-43 (2007)
65. Calvani M, R. Nicolai, A. Barbarisi, E. Reda, P. Benatti, & G. Peluso: Carnitine system and tumor. Adv Exp Med Biol 472:273-91 (1999)
66. Yee L.D., J.L. Lester, R.M. Cole, J.R. Richardson, J.C. Hsu, Y. Li, A. Lehman, M.A. Belury, & S.K. Clinton: Omega-3 fatty acid supplements in women at high risk of breast cancer have dose-dependent effects on breast adipose tissue fatty acid composition. Am J Clin Nutr 91 (5), 1185-94 (2010)
67. Milner, J.A.: Garlic: its anticarcinogenic and antitumorigenic properties. Nutr Rev 54 (11 Pt 2), S82-6 (1996);
68. Milner, J.A.: Preclinical perspectives on garlic and cancer. J Nutr 136 (3 Suppl), 827S-831S (2006
69. Powolny A.A., & S.V. Singh: Multitargeted prevention and therapy of cancer by diallyl trisulfide and related Allium vegetable-derived organosulfur compounds. Cancer Lett 8: 269 (2), 305-14 (2008)
70. Iciek M, I. Kwiecie?, & L. W?odek: Biological properties of garlic and garlic-derived organosulfur compounds. Environ Mol Mutagen 50 (3), 247-65 (2009
71. Howard E.W., D.T. Lee, Y.T. Chiu, C.W. Chua, X. Wang, & Y.C.Wong: Evidence of a novel docetaxel sensitizer, garlic-derived S- allylmercaptocysteine, as a treatment option for hormone refractory prostate cancer. Int J Cancer 122 (9), 1941-1948 (2008)
72. Mantle D., T.W. Lennard, & A.T. Pickering: Therapeutic applications of medicinal plants in the treatment of breast cancer: A review of their pharmacology, efficacy and tolerability. Adverse Drug React Toxicol Rev 19 (3), 223-40 (2000
73. Sun, J.: D-Limonene: safety and clinical applications. Altern Med Rev 12 (3), 259-64 (2007)
74. Igimi H, T. Hisatsugu, & M. Nishimura: The use of dlimonene preparation as a dissolving agent of gallstones. Am J Dig Dis 21, 926-939 (1976
75. Crowell P.L.: Prevention and therapy of cancer by dietary monoterpenes. J Nutr 129, 775S-778S (1999)
76. Vigushin DM, G.K. Poon, A. Boddy, J. English, G.W. Halbert, C. Pagonis, M. Jarman, & R.C. Coombes: Phase I and pharmacokinetic study of d-limonene in patients with advanced cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Cancer Chemother Pharmacol 42, 111-117 (1998
77. Beuth J.: Evidence-based complementary oncology: innovative approaches to optimise standard therapy strategies. Anticancer Res 30 (5), 1767-1771 (2010)
78. Tomillero A., & M. A. Moral: Gateways to clinical trials. Methods Find Exp Clin Pharmacol 32 (3),193-215 (2010)